Residual keratan sulfate in chondroitin sulfate formulations for oral administration  by Pomin, Vitor H. et al.
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a  b  s  t  r  a  c  t
Chondroitin  sulfate  is a biomedical  glycosaminoglycan  (GAG)  mostly  used  as  a dietary  supplement.  We
undertook  analysis  on  some  formulations  of  chondroitin  sulfates  available  for  oral  administration.  The
analysis was based  on  agarose-gel  electrophoresis,  strong  anion-exchange  chromatography,  digestibility
with  speciﬁc  GAG  lyases,  uronic  acid  content,  NMR  spectroscopy,  and  size-exclusion  chromatography.
Keratan  sulfate  was  detected  in  batches  from  shark  cartilage,  averaging  ∼16%  of the total  GAG.  Keratan
sulfate  is  an  inert  material,  and  hazardous  effects  due  to its  presence  in  these  formulations  are  unlikely
to occur.  However,  its unexpected  high  percentage  compromises  the  desired  amounts  of  the real  ingre-lycosaminoglycan
eratan sulfate
steoarthrosis
uality control
dient  speciﬁed  on  the  label  claims,  and  forewarns  the  pharmacopeias  to update  their  monographs.  The
techniques  they  recommended,  especially  cellulose  acetate  electrophoresis,  are  inefﬁcient  in detecting
keratan sulfate  in  chondroitin  sulfate  formulations.  In addition,  this  ﬁnding  also  alerts  the  manufacturers
for  improved  isolation  procedures  as well  as  the  supervisory  agencies  for better  audits.  Analysis  based
on strong  anion-exchange  chromatography  is shown  to be more  reliable  than  the  methods  presently
armasuggested  by  standard  ph
. Introduction
Glycosaminoglycans (GAGs) are widely used as therapeutic
gents (Gesselbauer & Kungl, 2006). In particular, heparin has been
argely exploited for treatments and preventions of thrombosis, and
n procedures involving extracorporeal circulation (Blossom et al.,
008). More recently, chondroitin sulfate, eventually in combina-
ion with glucosamine (Clegg et al., 2006), has been employed as an
lternative medicine in therapies for osteoarthritis, osteoarthrosis
nd possibly osteoporosis. Chondroitin sulfate formulations for oral
dministration are also used as a nutraceutical to prevent lesions of
Abbreviations: Chase AC, chondroitin AC lyase; COSY, correlation spectroscopy;
S(s), chondroitin sulfate(s); Eur, European; GAG(s), glycosaminoglycan(s); Gal,
alactose; GalNAc, N-acetylgalactosamine; GlcA, glucuronic acid; GlcNAc, N-
cetylglucosamine; GARP, globally optimized alternating phase rectangular pulses;
PLC, high-performance liquid chromatography; HSQC, heteronuclear single
uantum coherence; KS, keratan sulfate; KSase, keratanase; LC, liquid chromatog-
aphy; NMR, nuclear magnetic resonance; OSCS, oversulfated chondroitin sulfate;
AGE, polyacrylamide-gel electrophoresis; SAX, strong anion exchange; SEC, size-
xclusion chromatography.
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joint cartilage, for example, in cases of continuous physical impact
on the knees (Clegg et al., 2006; Volpi, 2007). In contrast to hep-
arin, which is used through intravascular or subcutaneous route;
as a dietary supplement, chondroitin sulfate is taken orally.
Chondroitin sulfate formulations are derived from different car-
tilage sources such as bovine tracheal, shark and whale cartilage.
However, the structure of chondroitin sulfate obtained from these
tissues varies signiﬁcantly, essentially due to variations of sul-
fation patterns of the N-acetylgalactosamine (GalNAc) residues,
such as 4-sulfation (CS-A) and 6-sulfation (CS-C) (Sugahara et al.,
2003). Other minor structural variations also occur, mainly as sul-
fation and epimerization extensions on the glucuronic acid (GlcA)
residues (Sugahara et al., 2003). The molecular size of chondroitin
sulfate chains may  also vary markedly among cartilage types (Leta,
Mourão, & Tovar, 2002). Another aggravating source of heterogene-
ity in preparations of chondroitin sulfate could be the undesirable
presence of trailing other GAG types due to imperfections in puriﬁ-
cation processes since these formulations are derived from animal
sources. In particular, keratan and heparan sulfates are other well-
known GAG components from cartilaginous proteoglycans. The
former GAG type has more structural similarities to chondroitin
sulfates than the latter. These similarities comprise the presence of
Open access under the Elsevier OA license.large extension in 6-O-sulfation, the lack of biosynthetic process-
ing at the N-position of hexosamines, and perhaps, polydispersity.
Hence, keratan sulfate is likely to present closer physicochemical
properties to chondroitin sulfate, and this may  leave some trailing
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mounts in large-scale production of chondroitin sulfates by raw
uriﬁcation procedures.
Herein we have analyzed several batches of chondroitin sulfate
ormulations readily available for oral administration, compared
o standards from the USA and European pharmacopeias. We
ndertook analysis using agarose-gel electrophoresis, strong-anion
xchange (SAX) and size-exclusion chromatography (SEC), both
oupled to a high-pressure liquid chromatography (HPLC) system,
igestibility with speciﬁc GAG lyases, estimation of uronic acid lev-
ls, and 1D + 2D nuclear magnetic resonance (NMR) spectroscopy.
e found that keratan sulfate averages around 16% of the total
AG amount found in the formulations speciﬁcally originating from
hark cartilage, including even the standard of the European phar-
acopeia which is essentially based on this cartilage type. The
eratan sulfate amount is far from a simple trace expectation,
nd strikingly indicates that more rigorous quality control tests
n chondroitin sulfate formulations are urged in order to assure
he proper efﬁcacy, and correct amount of the bioactive ingredient
n these formulations of chondroitin sulfate. Moreover, improved
uriﬁcation methods must be undertaken by manufacturers of this
aterial as well as audits from regulatory agencies.
. Materials and methods
.1. Samples of chondroitin sulfate formulation
Seventeen batches of chondroitin sulfate formulations readily
vailable for oral administration (fourteen from shark and three
rom bovine cartilage) were obtained from Brazilian pharmaceu-
ical companies. All batches come from a single manufacturer. Its
ame is kept anonymous due to ethical principles. Pharmacopeial
tandards of chondroitin sulfate were obtained from the USA
Rockville, MD;  cat. 1133570, Lot HOF184) and the European (Stras-
ourg, code Y0000593, ID. 002SJ4) pharmacopeias. Commercially
vailable chondroitin sulfate from shark (CS-C, predominantly 6-
ulfated) and whale (CS-A, mostly 4-sulfated) cartilage were from
igma–Aldrich (St. Louis, MO,  USA). Oversulfated chondroitin sul-
ate (OSCS) was prepared as described previously (Fonseca et al.,
010).
.2. Agarore gel electrophoresis
Aliquots of chondroitin sulfate (5 g of each) were applied to a
 mm-thick 0.5% agarose-gel, then run for 1 h at 110 V in 0.05 M
,3-diaminopropane:sodium acetate (pH 9.0). The GAGs in the gel
ere ﬁxed with 0.1% N-cetyl-N,N,N-trimethylammonium bromide
olution. After 12 h, the gel was dried and stained with 0.1% tolui-
ine blue in acetic acid:ethanol:water (0.1:5:5, v:v). This method is
imilar to one recommended by both USA (cellulose acetate elec-
rophoretic version) and European pharmacopeias for analysis of
hondroitin sulfate formulations (European Pharmacopeia, 2007;
nited States Pharmacopeia, 2008). It is hard to accurately predict
he amounts of GAGs based solely on agarose gel electrophoresis,
ince this procedure involves multiple steps such as precipitation
f the glycans in the gel with N-cetyl-N,N,N-trimethylammonium
romide, staining with toluidine blue, etc.
.3. SAX and SEC
GAG samples (1 mg  of each) were applied to a SAX Mono-Q col-
mn  pre-equilibrated with 10 mM Tris:HCl containing 0.5 M NaCl,
H 7.4 and connected to HPLC system (Amersham Biosciences). The
olumn was then washed with 10 mL  of the same Tris buffer and
luted at a ﬂow rate of 1.0 mL  min−1 using a linear NaCl gradient
f 0.5–3.0 M NaCl, total volume of 40 mL.  The eluent was checked
ontinuously by absorbance at 215 nm.  Chondroitin sulfates fromlymers 90 (2012) 839– 846
bovine cartilage (CS-A), from shark cartilage (CS-C), and keratan
sulfate from shark cartilage, eluted from the SAX-HPLC (Mono-Q
column) at 1.48, 1.66, and 2.2 M of NaCl, respectively.
For the preparation of large amounts of the individual GAG frac-
tions, 10 mg  of chondroitin sulfate formulation derived from shark
cartilage was applied to the column, which was eluted as described
in the previous paragraph. The fractions were individually col-
lected, desalted by dialysis against distilled water and freeze-dried.
The uronic acid content of these fractions was estimated using the
carbazole reaction (Bitter & Muir, 1962), and glucuronolactone as
standard.
For SEC, samples of chondroitin sulfates (20 g of each) were
analyzed with gel ﬁltration columns (Tosoh TSK gel G4000 SW × 1
and G3000 SW × 1, both 7.5 mm i.d. × 300 mm)  linked to an HPLC
system. To widen the molecular-weight exclusion limits, a combi-
nation of one G4000 column followed by one G3000 was used. The
columns were eluted with 0.1 M ammonium acetate, at room tem-
perature (∼20 ◦C) with a ﬂow rate of 0.3 mL  min−1. The eluent was
monitored by refractive index. The column was properly calibrated
using GAG standards with known molecular size.
2.4. Digestions with speciﬁc GAG lyases
Fractions of GAGs obtained from shark cartilage (100 g each)
were separately incubated with 0.01 units of chondroitin AC lyase
(Chase AC) (Sigma–Aldrich, St. Louis, MO)  or 0.2 units keratan sul-
fate lyase I (KSase) (Seikagaku American Inc, East Falmouth, MA),
in 100 L 0.05 M Tris:HCl (pH 8.0), with 5 mM  EDTA and 15 mM
sodium acetate. The mixtures were kept at 37 ◦C for 12 h. The
samples were then heated at dried-bath at 80 ◦C for 15 min  to neu-
tralize the reaction through enzyme denaturation. These samples
were subsequently analyzed on polyacrylamide-gel electrophore-
sis (PAGE) as described previously (Pomin, Valente, Pereira, &
Mourão, 2005). Essentially, aliquots containing 5 g of the dif-
ferent fractions incubated in the absence or presence of the GAG
lyases were applied to a 1-mm-thick 10% polyacrylamide-slab gel
in 0.02 M Tris:Cl (pH 8.6). After electrophoresis (100 V for ∼40 min),
the GAGs were stained with 0.1% toluidine blue in 1% acetic acid and
washed for about 1 h in 1% acetic acid.
2.5. NMR  spectroscopy
1H and 13C, one-dimensional and two-dimensional spectra of
the fractions obtained from shark cartilage were recorded using a
Bruker DRX 800 MHz  apparatus with a triple resonance probe as
detailed previously (Pomin et al., 2005). About 5 mg  of each sample
was dissolved in 0.6 mL  99.9% deuterium oxide (Cambridge Isotope
Laboratory, Cambridge, MA). All spectra were recorded at 35 ◦C
with HOD suppression by presaturation. The 1D 1H NMR  spectra
were recorded using 16 scans and inter-scan delay set to 1 s. The
2D 1H/1H COSY spectrum was recorded using states-time propor-
tion phase incrementation (states-TPPI) for quadrature detection in
the indirect dimension. The 1H/13C edited-HSQC spectrum was run
with 1024 × 256 points and globally optimized alternating phase
rectangular pulses (GARP) for decoupling. Chemical shifts are dis-
played relative to external trimethylsilylpropionic acid at 0 ppm for
1H and relative to methanol for 13C.
3. Results and discussion
Seventeen batches of chondroitin sulfate formulations read-
ily available for oral administration were analyzed by agarose-gel
electrophoresis, showing a single band with the same mobility
as the standards from USA and European pharmacopeias (Fig. 1).
No difference was observed between the electrophoretic migra-
tion of chondroitin sulfates from shark and bovine cartilage.
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Fig. 1. Agarose-gel electrophoresis of chondroitin sulfate standards from reference
pharmacopeias (American, USA-CS, and European, Eur-CS), oversulfated chondroitin
sulfate, and of formulation batches derived from shark and bovine cartilage.
Table 1
Proportions of chondroitin sulfate (CS) and keratan sulfate (KS) in batches of chon-
droitin sulfate formulations for oral administration, obtained from shark or bovine
cartilage, and pharmacopeial standards.a
Source Number of batches CS KS
% of total as mean ± SD
Shark cartilage 14 84.2 ± 1.4 15.8 ± 1.4
Bovine cartilage 3 100 <1
Standard from USA
pharmacopeia
1 100 <1
Standard from European
pharmacopeia
1 90 10a The proportions were obtained from the integrals of the SAX proﬁles of Fig. 2.
Table S1 shows the amounts of each batch.
Clearly, OSCS was  not detected in any of these batches using this
method. Although USA and European pharmacopeias (European
Pharmacopeia, 2007; United States Pharmacopeia, 2008) have
established cellulose acetate for analysis of chondroitin sulfate for-
mulations, agarose-gel electrophoresis is a similar methodological
version of horizontal electrophoresis.
Subsequently, the elution proﬁles of chondroitin sulfate formu-
lations obtained from shark and bovine cartilage were compared
using a SAX-HPLC (Mono-Q column) (Fig. 2). Bovine chondroitin
sulfate displayed a single peak (Fig. 2B) while batches obtained from
shark cartilage unexpectedly showed two distinct components
(Fig. 2A). The preponderant peak eluted as standard chondroitin
sulfate, notated as CS. The minor component, designated KS, eluted
at a higher NaCl concentration and accounts for approximately
16% of the total GAG amount found in the batches of chon-
droitin sulfate formulations obtained from shark cartilage analyzed
herein (Table 1). The standard obtained from USA pharmacopeia,
derived from bovine cartilage, showed just the single fraction CS,
as expected. The standard from European pharmacopeia obtained
from shark cartilage, conversely revealed both fractions as well
(Fig. 2B, Table 1).
Large amounts of the chondroitin and keratan sulfates frac-
tions were prepared from representative batches of shark cartilage
(Fig. 3A), and used afterwards for further uronic acid estimation,
susceptibility to speciﬁc GAG lyases, and NMR  structural analy-
sis. Fractions designated CS and KS were ultimately characterized
as chondroitin and keratan sulfate, respectively, based on the fol-
lowing data. Firstly, CS fraction contains uronic acid, which it
is absent in KS fraction (Fig. 3B). Secondly, CS and KS fractions
were susceptible to digestions with chondroitin AC lyase (Chase
AC) and keratanase (KSase), respectively, and properly resistant in
treatments using the unrelated lyases (Fig. 3C). More surprisingly
was that on agarose-gel electrophoresis, these two fractions were
seen undistinguishable since they co-migrate through this method
(Fig. 3D). Thirdly, these two  fractions were properly characterized
through high-ﬁeld NMR  spectroscopy (Figs. 4, 5 and S2). The 1H-
signal distribution in the spectrum of fraction CS is also similar to
that of CS-C obtained from Sigma–Aldrich (compare Figs. 4B vs S1A).
The GalNAc units in these samples are preponderantly 6-sulfated
(Pomin et al., 2012). 1H NMR  spectra of CS-A obtained from whale
or bovine tracheal cartilage showed an intense signal at 5.4 ppm
assigned as H4 of 4-sulfated GalNAc units (Fig. S1B). Overall, these
observations clearly indicate that fraction denoted CS is a chon-
droitin sulfate mostly 6-sulfated.
However, more signiﬁcantly, an 1H NMR  spectrum of fraction
KS showed a distinct peak distribution of 1H-signals compared
with those from fraction CS (Fig. 4B vs C). The 1H/1H COSY spec-
trum (Fig. S2), and especially the 1H/13C-HSQC spectrum (Fig. 5)
of fraction KS enabled proper assignment of many typical signals
of keratan sulfate-like molecule. Through the edited 1H/13C-HSQC
spectrum, in which the phased CH signals (orange signals in Fig. 5)
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Fig. 2. SAX-HPLC (Mono-Q column) proﬁles of chondroitin sulfate formulations readily available for oral administration obtained from shark (A), or bovine (B) cartilage.
Standards from pharmacopeias (USA-CS of bovine cartilage, and Eur-CS of shark cartilage origin) are shown in the bottom of panel (B). Peaks labeled with a question mark
are  uncharacterized materials.
Fig. 3. Analysis of puriﬁed CS and KS fractions through SAX-HPLC (Mono-Q column) (A), estimation of uronic acid content (B), PAGE before and after chondroitin AC lyase
(Chase  AC), or keratanase (KSase) treatment (C) and agarose-gel electrophoresis of a untreated representative chondroitin sulfate batch, puriﬁed fractions CS and KS, OSCS
and  standard from European pharmacopeia (Eur-CS).
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Fig. 4. 1D 1H NMR  spectra of a representative chondroitin sulfate preparation from shark cartilage (A), and its puriﬁed CS (B), and KS (C) fractions. U, A, N, and G stand for
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1lucuronic acid, N-acetylgalactosamine, N-acetylglucosamine, and galactose, respe
an be easily distinguished from anti-phased CH2 signals (in green),
everal structural information were generated as the following.
Firstly, two characteristic -anomeric 1H/13C-signals at
.68/102.85 and 4.49/102.93 ppm were identiﬁed, and respec-
ively attributed to residues of N-acetyl--glucosamine (GlcNAc)
denoted N1) and -galactose (Gal) (denoted G1) (Fig. 5 and
able 2). These signals are in approximately equimolar pro-
ortions, conceived with the disaccharide repeating unit of a
eratan sulfate-like molecule composed of alternating 4-linked
lcNAc and 3-linked Gal residues. Secondly, two clear signals
nvolved in glycosydic bonds are at 3.70/78.91 and 3.69/82.28 ppm
denoted N4 and G3 respectively in Fig. 5 and Table 2), typically of
3C-signals at downﬁeld region, as expected in the case of. The numbers after these letters indicate positions of hydrogen atoms.
glycosylation sites. These two cross-peaks belong to 1H/13C-signals
of 4-linked GlcNAc and 3-linked Gal residues consistent with the
glycosidic linkage type in keratan sulfate molecules (Table 2).
Gal units had a 1H-chemical shift of their H2 at ∼3.55 ppm, as
opposed to the upﬁeld ∼3.4 ppm for H2 of glucuronic acids (signal
U2 of spectrum of Fig. 4B), and to the downﬁeld ∼3.8 ppm for
H2 of GalNAc (signal N2 of spectrum at Fig. 5). Thirdly, the H2
assigned at ∼3.55 ppm through 1H–1H COSY spectrum of the
fraction KS (Fig. 2S)  unequivocally conﬁrms the presence of a Gal
unit (Table 2), and keratan sulfate is the only GAG type that bears
this neutral sugar instead of an uronic acid unit.
Finally, information about 6-sulfation of GlcNAc and Gal
residues was  easily deduced by analysis of the anti-phased peaks
844 V.H. Pomin et al. / Carbohydrate Polymers 90 (2012) 839– 846
Table  2
Major 1H and 13C-chemical shifts (ppm) from signals identiﬁed in the 2D NMR  spectra of KS fraction compared with literature data.
Signal Values from the present study Literature dataa
4--GlcNAc-1 (N) 3--Gal-1 (G) 4--GlcNAc-1 3--Gal-1
H1 4.69 4.49 4.76 4.54
H2  3.78 3.55 3.83 ND
H3  ND 3.70 ND 3.79
H4 3.71 ND ∼3.80 ND
Sulfated H6 4.37–4.23 4.20–4.08 4.32–4.39 4.22
C1  102.87 102.93 105 105
C2  55.13 69.97 57 ND
C3  ND 82.22 ND 85
C4 78.95 ND 81 ND
Sulfated C6 66.65 67.72 69 70
The sulfation and glycosilation sites are highlighted in bold and italics, respectively. ND s
a Cockin, Huckerby, and Nieduszynski (1986).
Fig. 5. 1H/13C edited HSQC spectrum of the fraction KS obtained. The letters N and G
stand for N-acetylgalactosamine and galactose, respectively. The numbers following
letters indicated position of 1H/13C cross-peaks. SO3− and non-SO3− stand for sul-
fated and non-sulfated sites. Green and orange peaks denote anti-phased (negative)
CH3 signals, and phased (positive) CH/CH2 peaks, respectively.tands for not determined.
shown in orange in Fig. 5. We can identify two signals at
4.37–4.23/66.58 and 4.20–4.08/67.67 ppm, ascribed to 6-sulfated
GlcNAc (N6 SO3−) and Gal (G6 SO3−) units, respectively (Table 2).
These signals are ∼0.7 ppm shifted downﬁeld in the 1H-scale and
∼8 ppm in the 13C-scale from a more heterogeneous group of
signals assigned to non-sulfated residues. Overall, these results
indicated clearly that KS fraction is indeed a keratan sulfate-like
molecule occurring with 6-sulfation at both residues, although
6-sulfation occurring more at GlcNAc units than usual (see peak-
intensities of sulfated Gal vs GlcNAc in Fig. 4C).
In order to prove the adequacy of SAX compared to the other
LC-based methods in detection of keratan sulfate in chondroitin
sulfate formulations readily available for oral administration, we
also undertook a systematic analysis using the SEC method. It is
well known that the molecular size range of chondroitin sulfate
(and probably keratan sulfate) varies signiﬁcantly depending on
the type of cartilage that is chosen for preparation (Leta et al.,
2002). Hence, this would consequently lead to some variation in
the SEC proﬁles for diagnostic purposes. Although chondroitin sul-
fate from shark and bovine tracheal (or whale) cartilage have very
disperse molecular size, ranging from ∼10 to ∼60 kDa (Pomin et al.,
2012), the major portions of each material are diagnostically dif-
ferent, and this difference can be used in assignments through
SEC as shown at Fig. 6. SEC-HPLC is clearly able to differentiate
the chondroitin sulfate types: shark cartilage CS-C vs bovine tra-
cheal CS-A or whale cartilage CS-A (Fig. 6), but not to distinguish
keratan sulfate from chondroitin sulfate, since the polydispersity
of keratan sulfate overlaps the peaks of any chondroitin sulfate
type (Fig. 6A). This reinforces that SAX chromatography coupled
to automatic fast LC systems is the most suitable LC-based method
for detecting keratan sulfate in formulations of chondroitin sul-
fates.
Chondroitin sulfates from bovine (CS-A), and from shark car-
tilage (CS-C) showed distinct SEC-HPLC proﬁles as seen by the
pharmacopeial standards from USA and Europe, respectively
(Fig. 6B). Samples mostly composed of C-type condroitin sulfate
elute earlier than A-types on SEC. This rule can also be seen com-
paring the readily available chondroitin sulfate standards (Fig. 6C).
In addition to the distinct SEC-HPLC proﬁles (Fig. 6C), these sam-
ples can also be distinguished and recognized by SAX-HPLC (Fig. S3).
Besides the marked differences in their molecular weights (Fig. 6C)
(Leta et al., 2002), these GAGs are well-known to differ in their 4-
/6-sulfation ratios (Pomin et al., 2012; Pomin, Sharp, Li, Wang, &
Prestegard, 2010), and this is the reason sustains SAX chromatog-
raphy useful for diagnostics of these chondroitin sulfate types.
Even though SEC reveals primarily a better resolution to distin-
guish between chondroitin sulfates (Figs. S3 vs 6C), this method
has proven incapable of detecting keratan sulfate in chondroitin
sulfate sample of any origin (Fig. 6).
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the general properties of the isolates are close to those of the realB) are uncharacterized materials.
In conclusion, formulations of chondroitin sulfate readily avail-
ble for oral administration obtained from cartilage of shark and
ovine origin differ in their content of residual keratan sulfate,
n their molecular size and sulfate of their GalNAc units. Several
ethods may  be employed to distinguish these two  types of prepa-
ations, but SAX chromatography coupled to automatic LC systems
ppears to be more reliable and robust implementation not only for
uality control of these GAG-based drug types but mainly to allow
ndustrial preparation of chondroitin sulfate samples distained of
arge amounts of the residual keratan sulfate. Results from this
uggestive method can be qualitatively enhanced by a combina-
ion with 1H-based NMR  analysis. This spectroscopic technique can
ltimately ensure the proper structural integrity of the bioactive
gent in biomedical formulations, together with a ﬁnal ﬁngerprint
f the batches prior to their release into the market. Presence oflymers 90 (2012) 839– 846 845
extra minor material can be straightforwardly checked using NMR
spectroscopy.
4. Conclusions
Herein, we  have reported a systematic analysis on 17 batches of
chondroitin sulfate formulations readily available for oral adminis-
tration. Agarose-gel electrophoresis was proven unable to reveal
residual keratan sulfate in these biomedical preparations since
these two  GAG type co-migrate (Fig. 3D). This electrophoretic
method is similar to the cellulose acetate version recommended by
USA and European pharmacopeias. In contrast, SAX-HPLC (Fig. 2),
but not SEC-HPLC (Fig. 6), has now proven to be the most appro-
priate method for detection of the eventual presence of keratan
sulfate, although SEC allows clear differentiation of chondroitin sul-
fates of different sources (bovine, whale and shark origin) (Fig. 6).
Therefore, anion exchange-based methods should be implemented
by manufacturers during large-scale production of chondroitin
sulfates samples destined to the market. It is also origin worth
mentioning that 1D 1H NMR  is very diagnostic for detection of
the keratan sulfate presence in formulations of chondroitin sulfate
as straightforwardly indicated by the well-resolved and isolated
groups of signals at 4.68 and 4.37–4.30 ppm in contaminated sam-
ples (compare Fig. 4A vs C). Clearly, this spectroscopic method
cannot be left aside in quality control tests of this drug type, and
should be used in conjunction with the SAX method prior to release
the ﬁnal chondroitin sulfate preparation into the market. Although
USA pharmacopeia recommends infrared spectroscopy and deter-
mination of the speciﬁc optical rotation, these methods have been
supplanted by NMR  spectroscopy for analysis of carbohydrates,
especially in GAG-based biomedical preparations (Limtiaco, Jones,
& Larive, 2012; Pomin et al., 2010; Rudd et al., 2011; Zhang et al.,
2009).
More trustworthy and robust procedures should be imple-
mented not only for control and regulation of chondroitin sulfate
formulations for oral administration, but also during industrial
preparation. And anion exchange-based methods have shown
herein to be the most feasible one to be implemented during man-
ufacturing. The occurrence of ∼16%-keratan sulfate indicates that
the biomedical formulations do not reﬂect the correct chondroitin
sulfate amounts speciﬁed with their label claims, and it is far out
from a simple expectation of trace amounts. A minimum of up-
to 5% presence of this inert GAG would be tolerated however, the
averaged amount evaluated herein extrapolate 3-times more the
maximum value of this reasonable range, and thus points to con-
siderable changes on the preparation and control procedures in
chondroitin sulfate formulations. Besides chondroitin and keratan
sulfate, a minor other substance was observed by LC, as marked
with question marks at Figs. 2A, B and 6B, C. Since it represents
much less than 5% of the tolerate percentage of impurities, this
material was not characterized. Cautions must be adopted in puriﬁ-
cation procedures of these chondroitin sulfate-based products by
the manufacturers, especially in products related with healthcare.
Although, puriﬁcation steps using anion exchange-based method
would reduce drastically the amounts of products per rounds of
preparation, the product generated would be much more reliable
than that based heavily on a crude isolation method procedure.
Curiously, contamination happened only on chondroitin sulfates
from shark origin. This source may  enhance the presence of con-
tamination, and manufacturers are also free to change to other
sources (whale or bovine cartilage rather than shark cartilage) ifdrug.
It is noteworthy to emphasize that only behind insulin the sec-
ond mostly used natural drug is heparin (Pomin & Mourão, 2008).
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hondroitin sulfate is undoubtedly the second mostly exploited
AG type in therapies. Its market has been growing rapidly world-
ide, especially in US as a dietary supplement, and therefore
hondroitin sulfate may  be assumed as the second carbohydrate-
ased bioagent utilized in the global market. It is very important
o highlight that the biomedical use of chondroitin sulfate is not
elated just only as a nutraceutical substance, but also involved
n many pharmaceutical applications such as in treatments of
nﬂammation, virosis, and cancer, wound healing, neuroprotec-
ion, wound repair keratinocytes, wound healing in maxillary sinus
ucosa, repair of the Central Nervous System, liver regeneration,
nd as potential antimalarial vaccine (Schiraldi, Cimini, & De Rosa,
010).
The previous alarming cases of OSCS-contaminated heparin
reparations (Blossom et al., 2008; Guerrini et al., 2008) strongly
einforce prompt and adequate reformulations of the standard
rocedures adopted by international pharmacopeias in quality
ontrols of GAG-based therapeutic agents. It is imperative that
AG-based preparations destined to either clinical use or as a
utraceutical must be distained at the maximum of impurities,
ven though of those with apparently harmless nature like another
hysiological GAG such as keratan sulfate. This should be a standard
rocedure to be followed to any pharmaceutical or a nutraceutical
roduct by any supplier committed with healthcare-related prod-
cts. The amount of the real ingredient in these formulations must
e correct.
Ultimately, it seems yet unclear the molecular basis for the
eneﬁcial effects of chondroitin sufates on osteoarthritis and
steoarthrosis. We  cannot predict if minor structural components
f this GAG type are in fact responsible for its beneﬁcial effects. But
e can anticipate that biomedical formulations of chondroitin sul-
ates covering a least uniform composition should be provided in
rder to maintain comparable clinical effects.
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